Company intelligence / Profile preview
Cellerant Therapeutics
San Carlos, California, United States
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Cellerant Therapeutics is developing cell and antibody-based immunotherapies. Their lead product Romyelocel-L (CLT-008) has advanced to Phase 3 for neutropenia. The company has several preclinical candidates including antibody-drug conjugates targeting solid tumors and acute myeloid leukemia.
- Therapeutic areas
- OncologyImmunologyRare DiseasesHematology
- Modalities
- Cell therapiesAntibody therapiesStem cell therapiesAntibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Biomedical Advanced Research and Development Authority (BARDA)
Beyond the preview
Go deeper on Cellerant Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellerant Therapeutics.